Celcuity (NASDAQ:CELC) Stock Rating Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Celcuity (NASDAQ:CELC) from a strong sell rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald assumed coverage on shares of Celcuity in a report on Thursday, October 22nd. They set an “overweight” rating and a $140.00 price objective on the stock. Stifel Nicolaus cut their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Guggenheim started coverage on Celcuity in a report on Friday, November 6th. They issued a “buy” rating and a $169.00 price objective on the stock. Needham & Company LLC cut their price objective on Celcuity from $140.00 to $134.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research note on Tuesday, September 1st. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Celcuity has an average rating of “Moderate Buy” and a consensus price target of $151.79.

Celcuity Price Performance

Shares of Celcuity stock traded up $0.20 on Friday, reaching $64.37. The company’s stock had a trading volume of 646,495 shares, compared to its average volume of 1,427,320. The company has a market capitalization of $3.16 billion, a P/E ratio of -13.67 and a beta of 0.16. Celcuity has a 52-week low of $53.54 and a 52-week high of $151.02. The stock has a 50-day moving average price of $72.47 and a 200-day moving average price of $98.23. The company has a quick ratio of 8.93, a current ratio of 14.62 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.30. Analysts expect that Celcuity will post -5.01 EPS for the current year.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently modified their holdings of CELC. PNC Financial Services Group Inc. lifted its holdings in Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after buying an additional 86 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after acquiring an additional 124 shares during the last quarter. Integrity Alliance LLC. increased its holdings in shares of Celcuity by 2.2% in the 3rd quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock valued at $944,000 after acquiring an additional 250 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Celcuity by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company’s stock worth $3,253,000 after acquiring an additional 297 shares in the last quarter. Finally, IFP Advisors Inc raised its position in shares of Celcuity by 42.6% during the 3rd quarter. IFP Advisors Inc now owns 995 shares of the company’s stock worth $79,000 after acquiring an additional 297 shares in the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.